Opko Health, Inc. (NASDAQ:OPK) saw a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 63,998,282 shares, a drop of 10.3% from the October 13th total of 71,351,349 shares. Based on an average daily volume of 3,460,691 shares, the short-interest ratio is currently 18.5 days. Approximately 19.4% of the company’s stock are short sold.

Shares of Opko Health (NASDAQ OPK) opened at $4.61 on Wednesday. Opko Health has a 1-year low of $4.55 and a 1-year high of $12.15. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. Opko Health’s quarterly revenue was down 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.03) EPS. research analysts forecast that Opko Health will post -0.2 EPS for the current fiscal year.

In other Opko Health news, CEO Phillip Md Et Al Frost bought 25,000 shares of the stock in a transaction on Monday, August 21st. The stock was purchased at an average price of $6.10 per share, for a total transaction of $152,500.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $18,720,601.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Opko Health, Inc. bought 655,738 shares of the stock in a transaction on Monday, October 30th. The shares were acquired at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the purchase, the insider now owns 6,678,752 shares of the company’s stock, valued at $20,370,193.60. The disclosure for this purchase can be found here. Insiders have bought 1,176,038 shares of company stock worth $5,126,540 in the last quarter. Insiders own 40.19% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cornerstone Capital Management Holdings LLC. raised its holdings in Opko Health by 611.8% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock worth $9,913,000 after buying an additional 1,242,272 shares during the period. Dimensional Fund Advisors LP raised its holdings in Opko Health by 127.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock worth $27,466,000 after buying an additional 2,241,103 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Opko Health by 43.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock worth $10,746,000 after buying an additional 471,256 shares during the period. Wells Fargo & Company MN raised its holdings in Opko Health by 14.3% during the 3rd quarter. Wells Fargo & Company MN now owns 481,085 shares of the biotechnology company’s stock worth $3,300,000 after buying an additional 60,177 shares during the period. Finally, Legal & General Group Plc raised its holdings in Opko Health by 17.4% during the 3rd quarter. Legal & General Group Plc now owns 141,535 shares of the biotechnology company’s stock worth $971,000 after buying an additional 21,017 shares during the period. Hedge funds and other institutional investors own 22.66% of the company’s stock.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a report on Tuesday. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a report on Saturday. Cantor Fitzgerald set a $20.00 price target on shares of Opko Health and gave the company a “buy” rating in a report on Wednesday, October 25th. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $16.00 price target on shares of Opko Health in a report on Monday, September 25th. Finally, J P Morgan Chase & Co downgraded shares of Opko Health from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $12.00 to $7.00 in a report on Thursday, September 14th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $13.97.

COPYRIGHT VIOLATION NOTICE: “Opko Health, Inc. (OPK) Short Interest Update” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/15/opko-health-inc-opk-short-interest-update.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.